Clinical Trials

  • Principal Investigator:

    Karen L. Bell, MD
    We are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks.
  • Principal Investigator:

    Karen L. Bell, MD
    We are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    The main goal of this study is to look at the effect and safety of efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP). Another goal of the study is to collect information on how well efgartigimod works, how the body processes efgartigimod, what efgartigimod does to the body, and how your immune system reacts to efgartigimod. This trial will be conducted in 2 stages: An open-label Stage A and a randomized-withdrawal, double-blind, placebo-controlled Stage B. Approximately 360 patients aged 18 years and older male and non-pregnant female are planned to...
  • Principal Investigator:

    Rebecca Straus Farber, MD
    The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on ocrelizumab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after the last Ocrelizumab (OCR) dose, prior to beginning DRF. Baseline visits for individuals remaining on OCR will take place prior to OCR dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-Hodgkins lymphoma.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    This study is a global multicenter, Phase 2, open-label, PoC study evaluating the efficacy, safety, and tolerability of SAR445088 administered to 3 subpopulations of patients with chronic inflammatory demyelinating polyneuropathy (CIDP): patients who are being treated with SOC therapies defined as intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), or corticosteroids; patients with CIDP who are refractory to SOC; and patients with CIDP who are nave to SOC. Adults 18 years of age at the time of signing the informed consent.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    Optune is a portable, battery-operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a novel type of cancer treatment that have been shown in laboratory studies to slow the growth of tumors, without causing significant side effects. In addition, the use of TTFields as a cancer treatment has been tested in numerous studies of...
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    Optune is a portable, battery-operated device that generates TTFields at a specific frequency. The TTFields are delivered to the brain through 4 sticky bandages (which hold ceramic discs) that are placed on the surface of the head (called arrays). The arrays create electric forces within the brain that disrupt cancer cell division. Optunes TTFields are a novel type of cancer treatment that has been shown in laboratory studies to slow the growth of tumors, without causing significant side effects. In addition, the use of TTFields as a cancer treatment has been tested in numerous studies of...

Pages